NeuroSense TherapeuticsNRSN
NRSN
About: NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Employees: 16
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 7 [Q2] → 7 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
8.11% less ownership
Funds ownership: 9.27% [Q2] → 1.16% (-8.11%) [Q3]
85% less capital invested
Capital invested by funds: $1.87M [Q2] → $286K (-$1.59M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for NRSN.
Financial journalist opinion
Based on 5 articles about NRSN published over the past 30 days
Neutral
PRNewsWire
3 days ago
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study Additionally, milestone payments and double-digit royalties on annual net sales The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025 CAMBRIDGE, Mass. , Dec. 23, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
1 week ago
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
2 weeks ago
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS CAMBRIDGE, Mass. , Dec. 11, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
3 weeks ago
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), demonstrated in a 58% improvement in survival rates Consistent data across subgroups underscore the potential of PrimeC to redefine the standard of care in the treatment of ALS CAMBRIDGE, Mass. , Dec. 4, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
3 weeks ago
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
CAMBRIDGE, Mass. , Dec. 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
1 month ago
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
CAMBRIDGE, Mass. , Nov. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
1 month ago
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory decision on commercialization expected by Q1 2026 CAMBRIDGE, Mass. , Oct. 28, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
2 months ago
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE, Mass. , Oct. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
2 months ago
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenue Company aims to expand approval efforts to additional global markets CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
2 months ago
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and improves survival rates by 43% Company plans to seek approval in additional countries CAMBRIDGE, Mass. , Oct. 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Charts implemented using Lightweight Charts™